Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
Yoshihiro Nishimura1,2, Maiko Taguchi1, Takafumi Nagai1, Masashi Fujihara1,2, Shigeru Honda2, Mamoru Uenishi11Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan; 2Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, JapanPurpose: To com...
Guardado en:
Autores principales: | Fujihara M, Nagai T, Taguchi M, Nishimura Y, Honda S, Uenishi M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/005882f722334a328436f33943897a4c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019) -
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017) -
Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sobha Sivaprasad
Publicado: (2008) -
Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji T, et al.
Publicado: (2013)